Literature DB >> 29713080

Complex formation between the vasopressin 1b receptor, β-arrestin-2, and the μ-opioid receptor underlies morphine tolerance.

Taka-Aki Koshimizu1, Kenji Honda2, Sachi Nagaoka-Uozumi2, Atsuhiko Ichimura3,4, Ikuo Kimura5, Michio Nakaya6, Nobuya Sakai7, Katsushi Shibata7, Kentarou Ushijima8, Akio Fujimura8, Akira Hirasawa9,10, Hitoshi Kurose6, Gozoh Tsujimoto9, Akito Tanoue11, Yukio Takano12.   

Abstract

Chronic morphine exposure upregulates adenylate cyclase signaling and reduces analgesic efficacy, a condition known as opioid tolerance. Nonopioid neurotransmitters can enhance morphine tolerance, but the mechanism for this is poorly understood. We show that morphine tolerance was delayed in mice lacking vasopressin 1b receptors (V1bRs) or after administration of V1bR antagonist into the rostral ventromedial medulla, where transcripts for V1bRs and μ-opioid receptors are co-localized. Vasopressin increased morphine-binding affinity in cells expressing both V1bR and μ-opioid receptors. Complex formation among V1bR, β-arrestin-2, and μ-opioid receptor resulted in vasopressin-mediated upregulation of ERK phosphorylation and adenylate cyclase sensitization. A leucine-rich segment in the V1bR C-terminus was necessary for the association with β-arrestin-2. Deletion of this leucine-rich segment increased morphine analgesia and reduced vasopressin-mediated adenylate cyclase sensitization. These findings indicate that inhibition of μ-opioid-receptor-associated V1bR provides an approach for enhancing morphine analgesia without increasing analgesic tolerance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29713080     DOI: 10.1038/s41593-018-0144-y

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  11 in total

Review 1.  Arrestin recruitment and signaling by G protein-coupled receptor heteromers.

Authors:  Kendall L Mores; Robert J Cassell; Richard M van Rijn
Journal:  Neuropharmacology       Date:  2018-11-09       Impact factor: 5.250

Review 2.  Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  MedComm (2020)       Date:  2022-06-22

Review 3.  Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects.

Authors:  Mariana Rae; Mariana Lemos Duarte; Ivone Gomes; Rosana Camarini; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2021-05-21       Impact factor: 9.473

4.  Circular RNA expression profile in the spinal cord of morphine tolerated rats and screen of putative key circRNAs.

Authors:  Yingqi Weng; Jing Wu; Lin Li; Jiali Shao; Zhengyiqi Li; Meiling Deng; Wangyuan Zou
Journal:  Mol Brain       Date:  2019-09-18       Impact factor: 4.041

5.  I8-arachnotocin-an arthropod-derived G protein-biased ligand of the human vasopressin V2 receptor.

Authors:  Leopold Duerrauer; Edin Muratspahić; Jasmin Gattringer; Peter Keov; Helen C Mendel; Kevin D G Pfleger; Markus Muttenthaler; Christian W Gruber
Journal:  Sci Rep       Date:  2019-12-17       Impact factor: 4.379

6.  Reduction of prefrontal purinergic signaling is necessary for the analgesic effect of morphine.

Authors:  Yeting Zeng; Huoqing Luo; Zilong Gao; Xiaona Zhu; Yinbo Shen; Yulong Li; Ji Hu; Jiajun Yang
Journal:  iScience       Date:  2021-02-20

7.  Dysregulation of Vesicular Glutamate Transporter VGluT2 via BDNF/TrkB Pathway Contributes to Morphine Tolerance in Mice.

Authors:  Liqiong He; Wei Xu; Chengliang Zhang; Zhuofeng Ding; Qulian Guo; Wangyuan Zou; Jian Wang
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.810

8.  Chronic developmental lead exposure increases μ-opiate receptor levels in the adolescent rat brain.

Authors:  Damaris Albores-Garcia; Jennifer L McGlothan; Zoran Bursac; Tomás R Guilarte
Journal:  Neurotoxicology       Date:  2020-11-25       Impact factor: 4.294

Review 9.  Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo.

Authors:  Muzeyyen Ugur; Lyes Derouiche; Dominique Massotte
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

10.  Agonist dependency of the second phase access of β-arrestin 2 to the heteromeric µ-V1b receptor.

Authors:  Nuttawadee Ngamlertwong; Hiroyoshi Tsuchiya; Yuta Mochimaru; Morio Azuma; Takahiro Kuchimaru; Taka-Aki Koshimizu
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.